Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02734615
Title Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU | BEL

Facility Status City State Zip Country Details
Massachusetts General Hospital Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
MD Anderson Cancer Center SC - LSZ102X2101 Houston Texas 77030 United States Details
Novartis Investigative Site Bruxelles 1200 Belgium Details
Novartis Investigative Site Lyon Cedex 69373 France Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Koto ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Singapore 169610 Singapore Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field